Meningiomas are usually considered to be benign central nervous system tumours but a significant fraction of patients with all types of meningiomas will eventually relapse. This pilot study intends to analyse the changes in the cell surface markers and internal cellular pathways of the tumour environment and correlate these findings to specific genetic changes seen in different types of meningiomas. Eventually, these results may lead to the identification of targets in patients with different types of meningiomas, allowing therapeutic treatments to be personalised.